March 26, 2018 / 4:36 PM / 6 months ago

BRIEF-Lysogene Had 14.1 Million Euros Of Cash And Cash Equivalent As Of December 31, 2017

March 26 (Reuters) - LYSOGENE SA:

* WELL POSITIONED TO START OUR PHASE III PIVOTAL TRIAL IN 2018 FOR LYS-SAF302

* LYSOGENE HAD EUR 14.1 MILLION OF CASH AND CASH EQUIVALENT AS OF DECEMBER 31, 2017.

* ALSO PLEASED WITH PROGRESS OF GM1 GANGLIOSIDOSIS PROGRAMME WITH GOAL TO START IN CLINICAL DEVELOPMENT IN 2019

* LOSSES PER SHARE INCREASED TO EUR 1.52 IN 2017 FROM EUR 0.91 IN 2016

* FY NET LOSS EUR 17.8 MILLION VERSUS LOSS EUR 7.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below